Farallon Capital Management’s Blueprint Medicines BPMC Stock Holding History

Farallon Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4,000	Closed	-$354K	–	147
2025 Q1	$354K	Hold	4,000	–	–	﹤0.01%	103
2024 Q4	$349K	Hold	4,000	–	–	﹤0.01%	107
2024 Q3	$370K	Hold	4,000	–	–	﹤0.01%	113
2024 Q2	$431K	Hold	4,000	–	–	﹤0.01%	112
2024 Q1	$379K	Hold	4,000	–	–	﹤0.01%	127
2023 Q4	$369K	Hold	4,000	–	–	﹤0.01%	116
2023 Q3	$201K	Sell	4,000 -18,420	-82%	-$984K	﹤0.01%	130
2023 Q2	$1.42M	Hold	22,420	–	–	0.01%	121
2023 Q1	$1.01M	Sell	22,420 -71,580	-76%	-$3.22M	0.01%	140
2022 Q4	$4.12M	Buy	+94,000	New	+$4.51M	0.02%	153
2022 Q3	–	Sell	-1,211,987	Closed	-$61.2M	–	313
2022 Q2	$61.2M	Sell	1,211,987 -145,000	-11%	-$8.49M	0.33%	67
2022 Q1	$86.7M	Buy	1,356,987 +545,240	+67%	+$39.1M	0.42%	53
2021 Q4	$86.9M	Sell	811,747 -132,656	-14%	-$13.9M	0.43%	51
2021 Q3	$97.1M	Sell	944,403 -180,597	-16%	-$16.8M	0.45%	56
2021 Q2	$99M	Buy	1,125,000 +430,209	+62%	+$39.4M	0.4%	53
2021 Q1	$67.6M	Buy	+694,791	New	+$69.4M	0.34%	60

Other funds holding BPMC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Farallon Capital Management's BPMC Position: Q2 2025 in Review

Farallon Capital Management sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 4,000 shares — an estimated $354K sold.

Farallon Capital Management first reported a position in BPMC in Q1 2021 and held it in 16 quarters. The position peaked at $99M in Q2 2021. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

Farallon Capital Management reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
Farallon Capital Management sold 4,000 Blueprint Medicines shares in Q2 2025, an estimated $354K.
Farallon Capital Management first reported a position in Blueprint Medicines in Q1 2021 and held it in 16 quarters.
Farallon Capital Management's Blueprint Medicines position peaked at $99M in Q2 2021.
354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Farallon Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.